SCHEMBL2193146

SCHEMBL2193146

Clc1ccc(CN(I)I)cc1.Cn1nc(C2CCCCC2)[nH]c1=[Pt]

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LSS P48449 3/20 0.38
CYP3A4 P08684 1/20 0.38
CYP2D6 P10635 1/20 0.38
CYP2C9 P11712 1/20 0.38
SLC6A2 P23975 1/20 0.38
SLC6A4 P31645 1/20 0.38
CYP2C19 P33261 1/20 0.38
SLC6A3 Q01959 1/20 0.38
PDE7A Q13946 3/20 0.34
PDE4D Q08499 2/20 0.34
PDE7B Q9NP56 1/20 0.34
ADORA1 P30542 2/20 0.33
ADORA3 P0DMS8 2/20 0.33
CNR2 P34972 1/20 0.33
PSEN1 P49768 2/20 0.32
PSEN2 P49810 2/20 0.32
APH1B Q8WW43 2/20 0.32
NCSTN Q92542 2/20 0.32
APH1A Q96BI3 2/20 0.32
PSENEN Q9NZ42 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2192454 0.90 ADORA1 (0.38) SLC6A2SLC6A4ADORA1CNR2SMN1; SMN2
SCHEMBL2193784 0.89 MAPK14 (0.36) CYP2D6SLC6A2SLC6A4SLC6A3ADORA1
SCHEMBL2192374 0.89 MEN1 (0.31) ACHEMEN1KMT2A
SCHEMBL2198292 0.89 ADORA3 (0.38) ADORA1ADORA3MEN1ALDH1A1KMT2A
SCHEMBL2195657 0.86 ADORA1 (0.41) SLC6A2SLC6A4ADORA1PSEN1PSEN2
SCHEMBL2195966 0.76 ADORA2A (0.33) CYP3A4ADORA1ADORA3SMN1; SMN2MAPK1
SCHEMBL2192944 0.76 ADORA2A (0.33) CYP3A4ADORA1ADORA3SMN1; SMN2MAPK1
SCHEMBL2268158 0.76 ADORA2A (0.33) CYP3A4ADORA1ADORA3SMN1; SMN2MAPK1
SCHEMBL2196243 0.76 ADORA2A (0.33) CYP3A4ADORA1ADORA3SMN1; SMN2MAPK1
SCHEMBL2194610 0.74 CYP19A1 (0.37) PDE7APDE4DSMN1; SMN2MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8980875-B2 Platinum-N-heterocyclic carbene derivatives, preparation thereof and therapeutic use thereof CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2015-03-17 US claimed
US-20130338128-A1 PLATINUM-N-HETEROCYCLIC CARBENE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2013-12-19 US claimed
US-8481522-B2 Platinum-N-heterocyclic carbene derivatives, preparation thereof and therapeutic use thereof SANOFI (FR) 2013-07-09 US claimed
US-20110172199-A1 PLATINUM-N-HETEROCYCLIC CARBENE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2011-07-14 US claimed
US-20110172199-A1 PLATINUM-N-HETEROCYCLIC CARBENE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2011-07-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130338128-A1 PLATINUM-N-HETEROCYCLIC CARBENE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SCO2, C3AR1, IDH1 LSS 4688/4885CYP3A4 1055/4885CYP2D6 463/4885
US-20110172199-A1 PLATINUM-N-HETEROCYCLIC CARBENE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SCO2, C3AR1, IDH1 LSS 4688/4885CYP3A4 1055/4885CYP2D6 463/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.